Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Samsung Biologics
Acquired Company
PolyPeptide Group AG
South Korea
SwitzerlandManufacturingBiotechnologyManufacturingBiotechnologyDescription
Samsung Biologics has secured 87.88% of Polypeptide Group through a successful tender offer, paving the way for its entry into the peptide business. The acquisition price is set at 1.46 billion Swiss francs, marking a significant move in Korea's pharmaceutical sector. Following regulatory approvals, the company plans to finalize the acquisition by the end of November. This acquisition will enable Samsung Biologics to diversify its offerings beyond antibody drugs.
Fundz sees it the moment Samsung Biologics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired PolyPeptide Group AG?
PolyPeptide Group AG was acquired by Samsung Biologics, based in South Korea. The deal was reported on October 13, 2026. Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that offers comprehensive services from cell line development to final aseptic fill/finish. Samsung Biologics is privately held and operates in Manufacturing.
When did Samsung Biologics acquire PolyPeptide Group AG?
Samsung Biologics's acquisition of PolyPeptide Group AG was reported on October 13, 2026. Samsung Biologics has secured 87.88% of Polypeptide Group through a successful tender offer, paving the way for its entry into the peptide business. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does PolyPeptide Group AG do?
PolyPeptide Group AG is a prominent contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). It is privately held, operating in Manufacturing, and is based in Switzerland.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.